Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab)
NCT ID: NCT02101307
Last Updated: 2017-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2014-07-09
2017-05-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RA Patients on RoActemra/Actemra treatment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a diagnosis of moderate to severe RA according to the revised (1987) ACR criteria
* Patient in whom the treating physician has made the decision to commence RoActemra/Actemra treatment (in accordance with the local label). This can include patients who have received RoActemra/Actemra treatment within 8 weeks prior to the enrolment visit
* Patient has given informed consent
Exclusion Criteria
* Patients who have previously received RoActemra/Actemra in a clinical trial or for compassionate use
* Patients who have received treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra
* Patients with a history of autoimmune disease or of any joint inflammatory disease other than RA
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, , China
Peking University Third Hospital
Beijing, , China
Beijing Union Hospital
Beijing, , China
Xiangya Hospital of Centre-South University
Changsha, , China
West China Hospital, Sichuan University
Chengdu, , China
Sichuan Provincial People's Hospital
Chengdu, , China
Southwest Hospital , Third Military Medical University
Chongqing, , China
Sun Yat-sen Memorial Hospital
Guangzhou, , China
Nanfang Hospital, Southern Medical University
Guangzhou, , China
The First Affiliated Hospital of Jinan University
Guangzhou, , China
TCM-Integrated Hospital of Southern Medical University
Guangzhou, , China
Zhejiang People's Hospital
Hangzhou, , China
Affiliated Hospital of Inner Mongolia Medical College
Hohhot, , China
The First People's Hospital of Yunnan Province
Kunming, , China
The First Affiliated Hospital of Henan UN of Science and Technology
Luoyang, , China
Affiliated Hospital of North Sichuan Medical College
Nanchong, , China
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, , China
Futian District people's Hospital of Shenzhen City
Shenzhen, , China
Xinjiang Uygur Autonomous Region People Hospital
Ürümqi, , China
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
Wuhan, , China
Wuxi People's Hospital
Wuxi, , China
The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital)
Xi'an, , China
The First Affiliated Hospital of Xiamen University
Xiamen, , China
YanTaishan Hospital of Yantai City
Yantai, , China
Zhuzhou Central Hospital
Zhuzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML28429
Identifier Type: -
Identifier Source: org_study_id